Information Regarding SARS-CoV-2 Strains and Reagents
FAQs
Materials Available
Coming Soon
Forms
BEI Resources is prioritizing and fast tracking all SARS-CoV-2 registrations and orders. We anticipate a 12-72 hour turn-around time for all SARS-CoV-2 related registrations and a 24-48 hour turn-around time on approved orders. Please indicate SARS-CoV-2 in your scope of use in your registration paperwork. Please contact BEI Resources at contact@beiresources.org for questions.
BEI Resources is working to accession strains of the 2019 novel coronavirus, recently named SARS-CoV-2, identified as the causative agent of the COVID-19 pandemic. We understand how important it is to share virus strains and derivatives with researchers; please contact us if you have suggestions for expanding our catalog offerings.
Currently Available SARS-CoV-2 Materials
*Please see the Appendix section of the COA for variant analysis of each virus lot.
BEI
Number |
Description |
Lineage |
GISAID
Clade |
GISAID ID |
Clinical Information Available |
Registration |
AA Substitutions
per GISAID* |
| Virus |
|
| NR-54982 |
SARS-CoV-2 Isolate hCoV-19/Japan/TY7-503/2021 |
P.1. (or 20J/501Y.V3) |
GR |
EPI_ISL_792683 (P0) and EPI_ISL_877769 (passage 1 in Vero E6 /TMPSS2*) *contains a F184V mutation compared with sequence from original sample. |
Isolated in airport quarantine station in Japan from a COVID-19 positive passenger from Brazil in January 2021. |
BEI Level 3 |
Link to Mutations |
| NR-54011 |
SARS-CoV-2 Isolate hCoV-19/USA/CA_CDC_5574/2020 |
B.1.1.7 |
GR |
EPI_ISL_751801 |
Isolated from a nasopharyngeal swab collected on December 29, 2020 in San Diego County, California, USA |
BEI Level 3 |
Link to Mutations |
| NR-54009 |
SARS-CoV-2 Isolate hCoV-19/South Africa/KRISP-K005325/2020 |
B.1.351 |
GH |
EPI_ISL_678615 |
Isolated from an oropharyngeal swab from a 40-year-old human male in Ugu district, KwaZulu-Natal, South Africa on November 16, 2020 |
BEI Level 3 |
Link to Mutations |
| NR-54008 |
SARS-CoV-2 hCoV-19/South Africa/KRISP-EC-K005321/2020 |
B.1.351 |
GH |
EPI_ISL_678570 |
Isolated from an oropharyngeal swab from a 57-year-old human male in Harry Gwala district, KwaZulu-Natal, South Africa on November 15, 2020 |
BEI Level 3 |
Link to Mutations |
| NR-54000 |
SARS-CoV-2 hCoV-19/England/204820464/2020 |
B.1.1.7 |
GR |
EPI_ISL_683466 |
Isolated from a 58-year-old human male on November 24, 2020 in England, United Kingdom. |
BEI Level 3 |
Link to Mutations |
| NR-53953 |
SARS-CoV-2, Isolate hCoV-19/Denmark/DCGC-3024/2020 (also referred to as SARS-CoV-2/hu/DK/CL-5/1) |
B.1.1.298 |
GR |
EPI_ISL_616802 |
Isolated from a human who was exposed to a COVID-19 infected European mink (Mustela lutreola) in Northern Jutland, Denmark on October 5, 2020. |
BEI Level 3 |
Link to Mutations |
| NR-53945 |
SARS-CoV-2, Isolate hCoV-19/Scotland/CVR2224/2020 |
B.1.222 |
G |
EPI_ISL_448167 |
Isolated from a throat swab from a human patient diagnosed with COVID-19, on July 17, 2020 in Scotland, United Kingdom |
BEI Level 3 |
Link to Mutations |
| NR-53944 |
SARS-CoV-2, Isolate hCoV-19/Scotland/CVR837/2020 |
B.1.5 |
G |
EPI_ISL_461705 |
Isolated from a throat swab from a human patient diagnosed with COVID-19, on July 17, 2020 in Scotland, United Kingdom |
BEI Level 3 |
Link to Mutations |
| NR-52281 |
SARS-CoV-2, Isolate USA-WA1/2020 |
A |
S |
EPI_ISL_404895 |
Male in 30s, returning traveler from Wuhan. Mild disease; recovered. |
BEI Level 3 |
|
| NR-52282 |
SARS-CoV-2, Isolate Hong Kong/VM20001061/2020 |
A |
S |
EPI_ISL_412028 |
Isolated from a nasopharyngeal aspirate and throat swab from an adult male patient on January 22, 2020 in Hong Kong |
BEI Level 3 |
|
| NR-52284 |
SARS-CoV-2, Isolate Italy-INMI1 |
None |
O |
EPI_ISL_406959 (fragment) |
Isolated from sputum of a patient with a respiratory illness who had recently returned from travel to the affected region of China and developed clinical disease (COVID-19) in January 2020 in Rome, Italy. |
BEI Level 3 |
|
| NR-52359 |
SARS-CoV-2, Isolate England/02/2020 |
A |
S |
EPI_ISL_407073 |
39 yr old Male; Isolated from Nasopharyngeal aspirate & Throat swab |
BEI Level 3 |
|
| NR-52368 |
SARS-CoV-2, Isolate New York 1-PV08001/2020 |
B.4 |
O |
EPI_ISL_414476 |
39 yr old Female; history of travel to Iran |
BEI Level 3 |
|
| NR-52369 |
SARS-CoV-2, Isolate Singapore/2/2020 |
B |
L |
EPI_ISL_407987 |
Isolated from a throat swab. Patient has respiratory illness, fever and cough |
BEI Level 3 |
|
| NR-52370 |
SARS-CoV-2, Isolate Germany/BavPat1/2020 |
B |
G |
EPI_ISL_406862 |
Isolated from Nasopharyngea swab. Typical symptoms of mild upper respiratory tract disease (D614G mutation) |
BEI Level 3 |
|
| NR-52381 |
SARS-CoV-2, Isolate USA-IL1/2020 |
B |
O |
EPI_ISL_404253 |
63 yr old Female; Isolated from sputum |
BEI Level 3 |
|
| NR-52382 |
SARS-CoV-2, Isolate USA-CA1/2020 |
A |
S |
EPI_ISL_406034 |
38 yr old Male; Isolated from nasopharyngeal swab |
BEI Level 3 |
|
| NR-52383 |
SARS-CoV-2, Isolate USA-AZ1/2020 |
A |
S |
EPI_ISL_406223 |
26 yr old Male; Isolated from bucal swab |
BEI Level 3 |
|
| NR-52384 |
SARS-CoV-2, Isolate USA-WI1/2020 |
B |
L |
EPI_ISL_408670 |
52 yr old Female; Isolated from nasopharyngeal swab |
BEI Level 3 |
|
| NR-52385 |
SARS-CoV-2, Isolate USA-CA3/2020 |
B |
L |
EPI_ISL_408008 |
72 yr old Female; Isolated from oropharyngeal swab |
BEI Level 3 |
|
| NR-52386 |
SARS-CoV-2, Isolate USA-CA4/2020 |
B |
L |
EPI_ISL_408009 |
57 yr old Male; Isolated from nasopharyngeal swab |
BEI Level 3 |
|
| NR-52387 |
SARS-CoV-2, Isolate USA-CA2/2020 |
B.2 |
O |
EPI_ISL_406036 |
54 yr old Male; Isolated from nasopharyngeal swab |
BEI Level 3 |
|
| NR-52439 |
SARS-CoV-2, Isolate Chile/Santiago_op4d1/2020 |
A.2 |
S |
EPI_ISL_415661 |
Isolated from a Nasal Swab. Patient has respiratory tract infection. History of travel to Europe |
BEI Level 3 |
|
| NR-53514 |
SARS-CoV-2, Isolate New York-PV08410/2020 |
B.1 |
GH |
EPI_ISL_421374 |
63 yr old Male; severe COVID19 with fatal outcome |
BEI Level 3 |
|
| NR-53515 |
SARS-CoV-2, Isolate New York-PV08449/2020 |
B.1 |
GH |
EPI_ISL_421400 |
88 yr old Female; severe COVID19 with fatal outcome |
BEI Level 3 |
|
| NR-53516 |
SARS-CoV-2, Isolate New York-PV09158/2020 |
B.1.3 |
GH |
EPI_ISL_422525 |
62 yr old Male; severe COVID19 with fatal outcome |
BEI Level 3 |
|
| NR-53517 |
SARS-CoV-2, Isolate New York-PV09197/2020 |
B.1.3 |
GH |
EPI_ISL_422552 |
90 yr old Male; severe COVID19 with fatal outcome |
BEI Level 3 |
|
| NR-53565 |
SARS-CoV-2, Isolate Canada/ON/VIDO-01/2020 |
B |
L |
EPI_ISL_425177 |
Isolated from a human patient sample collected on January 23, 2020 in Ontario, Canada |
BEI Level 3 |
|
| NR-52390 |
Adenovirus Serotype 5, Clone Ad5-CMV-hACE2/RSV-eGFP, Recombinant Expressing Human ACE2 |
BEI Level 2 |
|
| NR-55329 |
SARS-CoV-2, Mouse-Adapted, MA10 Variant (in isolate USA-WA1/2020 backbone), Infectious Clone (ic2019-nCoV MA10) in Calu-3 Cells |
BEI Level 3 |
|
| Nucleic Acid |
|
| NR-55244 |
Genomic RNA from SARS-CoV-2 Isolate hCoV-19/USA/CA_CDC_5574/2020 |
B.1.1.7 |
GR |
EPI_ISL_751801 |
Isolated from a nasopharyngeal swab collected on December 29, 2020 in San Diego County, California, USA |
BEI Level 2 |
Link to Mutations |
| NR-52285 |
Genomic RNA from SARS-CoV-2, Isolate USA-WA1/2020 |
A |
S |
EPI_ISL_404895 |
Male in 30s, returning traveler from Wuhan. Mild disease; recovered. |
BEI Level 2 |
|
| NR-52388 |
Genomic RNA from SARS-CoV-2, Isolate Hong Kong/VM20001061/2020 |
A |
S |
EPI_ISL_412028 |
Isolated from a nasopharyngeal aspirate and throat swab from an adult male patient on January 22, 2020 in Hong Kong |
BEI Level 2 |
|
| NR-52498 |
Genomic RNA from SARS-CoV-2, Isolate Italy-INMI1 |
None |
O |
EPI_ISL_406959 (fragment) |
Isolated from sputum of a patient with a respiratory illness who had recently returned from travel to the affected region of China and developed clinical disease (COVID-19) in January 2020 in Rome, Italy. |
BEI Level 2 |
|
| NR-52499 |
Genomic RNA from SARS-CoV-2, Isolate England/02/2020 |
A |
S |
EPI_ISL_407073 |
39 yr old Male; Isolated from Nasopharyngeal aspirate & Throat swab |
BEI Level 2 |
|
| NR-52501 |
Genomic RNA from SARS-CoV-2, Isolate Singapore/2/2020 |
B |
L |
EPI_ISL_407987 |
Isolated from a throat swab. Patient has respiratory illness, fever and cough |
BEI Level 2 |
|
| NR-52502 |
Genomic RNA from SARS-CoV-2, Isolate Germany/BavPat1/2020 |
B |
G |
EPI_ISL_406862 |
Isolated from Nasopharyngea swab. Typical symptoms of mild upper respiratory tract disease (D614G mutation) |
BEI Level 2 |
|
| NR-52503 |
Genomic RNA from SARS-CoV-2, Isolate USA-IL1/2020 |
B |
O |
EPI_ISL_404253 |
63 yr old Female; Isolated from sputum |
BEI Level 2 |
|
| NR-52504 |
Genomic RNA from SARS-CoV-2, Isolate USA-CA1/2020 |
A |
S |
EPI_ISL_406034 |
38 yr old Male; Isolated from nasopharyngeal swab |
BEI Level 2 |
|
| NR-52505 |
Genomic RNA from SARS-CoV-2, Isolate USA-AZ1/2020 |
A |
S |
EPI_ISL_406223 |
26 yr old Male; Isolated from bucal swab |
BEI Level 2 |
|
| NR-52506 |
Genomic RNA from SARS-CoV-2, Isolate USA-WI1/2020 |
B |
L |
EPI_ISL_408670 |
52 yr old Female; Isolated from nasopharyngeal swab |
BEI Level 2 |
|
| NR-52507 |
Genomic RNA from SARS-CoV-2, Isolate USA-CA3/2020 |
B |
L |
EPI_ISL_408008 |
72 yr old Female; Isolated from oropharyngeal swab |
BEI Level 2 |
|
| NR-52508 |
Genomic RNA from SARS-CoV-2, Isolate USA-CA4/2020 |
B |
L |
EPI_ISL_408009 |
57 yr old Male; Isolated from nasopharyngeal swab |
BEI Level 2 |
|
| NR-52509 |
Genomic RNA from SARS-CoV-2, Isolate USA-CA2/2020 |
B.2 |
O |
EPI_ISL_406036 |
54 yr old Male; Isolated from nasopharyngeal swab |
BEI Level 2 |
|
| NR-52510 |
Genomic RNA from SARS-CoV-2, Isolate Chile/Santiago_op4d1/2020 |
A.2 |
S |
EPI_ISL_415661 |
Isolated from a Nasal Swab. Patient has respiratory tract infection. History of travel to Europe |
BEI Level 2 |
|
| NR-53518 |
Genomic RNA from SARS-CoV-2, Isolate New York-PV08410/2020 |
B.1 |
GH |
EPI_ISL_421374 |
63 yr old Male; severe COVID19 with fatal outcome |
BEI Level 2 |
|
| NR-52346 |
Quantitative PCR (qPCR) Control RNA from Inactivated SARS Coronavirus, Urbani |
BEI Level 1 |
|
| NR-52347 |
Quantitative PCR (qPCR) Control RNA from Heat-Inactivated SARS-CoV-2, Isolate USA-WA1/2020 |
BEI Level 1 |
|
| Inactivated Organisms |
|
| NR-55245 |
SARS-CoV-2, Isolate USA/CA_CDC_5574/2020, Heat Inactivated (B.1.1.7) |
BEI Level 1 |
|
| NR-52286 |
SARS-CoV-2, Isolate USA-WA1/2020, Heat Inactivated |
BEI Level 1 |
|
| NR-52287 |
SARS-CoV-2, Isolate USA-WA1/2020, Gamma-Irradiated |
BEI Level 1 |
|
| NR-52349 |
Quantitative PCR (qPCR) Extraction Control from Inactivated SARS Coronavirus, Urbani |
BEI Level 1 |
|
| NR-52350 |
Quantitative PCR (qPCR) Extraction Control from Heat-Inactivated SARS-CoV-2, Isolate USA-WA1/2020 |
BEI Level 1 |
|
| Cell Line |
|
| NR-53258 |
Vero E6 Cell Lysate Control, Gamma-Irradiated (To be used with NR-52287) |
BEI Level 1 |
|
| NR-53522 |
Human Lung Carcinoma Cells (A549) Expressing Human Angiotensin-Converting Enzyme 2 (HA-FLAG) |
BEI Level 1 |
|
| NR-53726 |
African Green Monkey Kidney Epithelial Cells (Vero E6) Expressing High Endogenous Angiotensin-Converting Enzyme 2 |
BEI Level 2 |
|
| NR-53821 |
Human Lung Carcinoma Cells (A549) Expressing Human Angiotensin-Converting Enzyme 2 |
BEI Level 1 |
|
| Monoclonal Antibody |
|
| NR-52481 |
Monoclonal Anti-SARS Coronavirus Recombinant Human Antibody, Clone CR3022 (produced in HEK293 Cells) |
BEI Level 1 |
|
| NR-53787 |
Monoclonal Anti-SARS Coronavirus Spike Glycoprotein S1 Domain (produced in vitro) |
BEI Level 1 |
|
| NR-53789 |
Monoclonal Anti-SARS Coronavirus/SARS-CoV-2 Spike Glycoprotein Receptor Binding Domain (RBD), Chimeric Antibody (produced in vitro) |
BEI Level 1 |
|
| NR-53790 |
Monoclonal Anti-SARS Coronavirus/SARS-CoV-2 Spike Glycoprotein Receptor Binding Domain (RBD), Chimeric Antibody (produced in vitro) |
BEI Level 1 |
|
| NR-53793 |
Monoclonal Anti-SARS-CoV-2 Nucleocapsid Protein (produced in vitro) |
BEI Level 1 |
|
| NR-53794 |
Monoclonal Anti-SARS Coronavirus/SARS-CoV-2 Nucleocapsid Protein (produced in vitro) |
BEI Level 1 |
|
| NR-53795 |
Monoclonal Anti-SARS-CoV-2 Spike Glycoprotein RBD-mFc Fusion Protein (produced in vitro) |
BEI Level 1 |
|
| NR-53796 |
Monoclonal Anti-SARS-CoV-2 Spike RBD-mFc Fusion Protein (produced in vitro) |
BEI Level 1 |
|
| NR-53876 |
Monoclonal Anti-SARS Coronavirus Recombinant Human IgG1, Clone CR3022 (produced in Nicotiana benthamiana) |
BEI Level 1 |
|
| Serum/Plasma |
|
| NR-52401 |
Pooled Non-Human Primate Convalescent Serum to SARS-CoV-2, Gamma-Irradiated |
BEI Level 2 |
|
| NR-52947 |
Polyclonal Anti-SARS-CoV-2 Spike Glycoprotein (IgG, Rabbit) |
BEI Level 1 |
|
| Protein |
|
| NR-52307 |
Spike Glycoprotein RBD from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from Baculovirus |
BEI Level 1 |
|
| NR-52308 |
Spike Glycoprotein (Stabilized) from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from Baculovirus (This item replaces NR-52396) |
BEI Level 1 |
|
| NR-52366 |
Spike Glycoprotein RBD from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from HEK293 Cells (This item replaces NR-52306) |
BEI Level 1 |
|
| NR-52397 |
Spike Glycoprotein (Stabilized) from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from HEK293F Cells |
BEI Level 1 |
|
| NR-52724 |
Spike Glycoprotein (Stabilized) from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine and Twin-Strep® Tags, Recombinant from HEK293 Cells
(related product for NR-53257) |
BEI Level 1 |
|
| NR-52946 |
Spike Glycoprotein RBD from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from HEK293T Cells |
BEI Level 1 |
|
| NR-53246 |
Nucleocapsid Protein N-Terminal RNA Binding Domain from SARS-CoV-2, Wuhan-Hu-1 with N-Terminal Histidine Tag, Recombinant from E. coli |
BEI Level 1 |
|
| NR-53524 |
Spike Glycoprotein (Stabilized) from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine and Avi Tags, Recombinant from HEK293F Cells |
BEI Level 1 |
|
| NR-53589 |
Spike Glycoprotein (Stabilized) from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine and Twin-Strep® Tags, Recombinant from HEK293 Cells |
BEI Level 1 |
|
| NR-53769 |
Spike Glycoprotein (Stabilized) from SARS-CoV-2, Wuhan-Hu-1 HexaPro with C-Terminal Histidine and Twin-Strep® Tags, Recombinant from CHO Cells |
BEI Level 1 |
|
| NR-53798 |
Spike Glycoprotein S1 Domain from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from HEK293 Cells |
BEI Level 1 |
|
| NR-53799 |
Spike Glycoprotein S2 Extracellular Domain (ECD) from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from Baculovirus |
BEI Level 1 |
|
| NR-53800 |
Spike Glycoprotein RBD from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from HEK293 Cells |
BEI Level 1 |
|
| NR-53937 |
Spike Glycoprotein (Stabilized) from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine and Twin-Strep® Tags, Recombinant from CHO Cells |
BEI Level 1 |
|
| NR-54004 |
Spike Glycoprotein RBD from SARS-CoV-2, United Kingdom Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells |
BEI Level 1 |
|
| NR-54005 |
Spike Glycoprotein RBD from SARS-CoV-2, South Africa Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells |
BEI Level 1 |
|
| Peptide Array |
|
| NR-52405 |
Peptide Array, SARS-CoV-2 Envelope (E) Protein |
BEI Level 1 |
|
| NR-52418 |
Peptide Array, SARS Coronavirus Spike (S) Protein |
BEI Level 1 |
|
| NR-52419 |
Peptide Array, SARS Coronavirus Nucleocapsid (N) Protein |
BEI Level 1 |
|
| Plasmid |
|
| NR-53816 |
SARS-CoV-2, Wuhan-Hu-1 Spike-Pseudotyped Lentiviral Kit V2 |
BEI Level 1 |
|
| NR-53817 |
SARS-CoV-2, Wuhan-Hu-1 Spike D614G-Pseudotyped Lentiviral Kit |
BEI Level 1 |
|
| NR-53260 |
Plasmid Set for Anti-SARS Coronavirus Human Monoclonal Antibody CR3022 |
BEI Level 1 |
|
| NR-54972 |
pSMART® BAC V2.0 Vector Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Infectious Replicon |
BEI Level 1 |
|
| NR-53742 |
Vector pHDM Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Gene with C-Terminal Deletion |
BEI Level 1 |
|
| NR-53765 |
Vector pHDM Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Gene, D614G Mutant with C-Terminal Deletion |
BEI Level 1 |
|
| NR-52309 |
Vector pCAGGS Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Gene RBD with C-Terminal Hexa-Histidine Tag |
BEI Level 1 |
|
| NR-52310 |
Vector pCAGGS Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Gene |
BEI Level 1 |
|
| NR-52394 |
Vector pCAGGS Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Gene (soluble, stabilized) |
BEI Level 1 |
|
| NR-52420 |
Vector pcDNA3.1(-) Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Gene |
BEI Level 1 |
|
| NR-52421 |
Vector pCMV Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Ectodomain |
BEI Level 1 |
|
| NR-52422 |
Vector pcDNA3.1(-) Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein RBD |
BEI Level 1 |
|
| NR-52423 |
Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 SARS-CoV Unique Domain Gene |
BEI Level 1 |
|
| NR-52424 |
Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 9 Gene |
BEI Level 1 |
|
| NR-52425 |
Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 10 Gene |
BEI Level 1 |
|
| NR-52426 |
Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 15 Gene |
BEI Level 1 |
|
| NR-52427 |
Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 16 Gene |
BEI Level 1 |
|
| NR-52428 |
Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein N-Terminal Domain |
BEI Level 1 |
|
| NR-52429 |
Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Nucleocapsid Protein RNA Binding Domain Gene |
BEI Level 1 |
|
| NR-52430 |
Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein RBD |
BEI Level 1 |
|
| NR-52431 |
Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 8 Gene |
BEI Level 1 |
|
| NR-52432 |
Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 7 Gene |
BEI Level 1 |
|
| NR-52433 |
Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 14 Gene |
BEI Level 1 |
|
| NR-52434 |
Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 Nucleocapsid Protein C-Terminal Domain Gene |
BEI Level 1 |
|
| NR-52435 |
Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 4 Gene, Cytoplasmic C-Terminal Domain |
BEI Level 1 |
|
| NR-52436 |
Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 Papain-Like Protease Gene |
BEI Level 1 |
|
| NR-52437 |
Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 3C-Like Protease Gene |
BEI Level 1 |
|
| NR-52438 |
Vector pET-11a Containing the SARS-CoV-2, Wuhan-Hu-1 ADP-Ribose-Phosphatase (ADRP) Gene |
BEI Level 1 |
|
| NR-52512 |
Vector pHAGE2 Containing the Angiotensin-Converting Enzyme 2 Gene |
BEI Level 1 |
|
| NR-52513 |
Vector pHDM Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Ectodomain Mutant, HA Tag |
BEI Level 1 |
|
| NR-52514 |
Vector pHDM Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein |
BEI Level 1 |
|
| NR-52515 |
Vector pHDM Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Ectodomain Mutant ALAYT |
BEI Level 1 |
|
| NR-52520 |
Vector pHAGE2 Containing the ZsGreen Gene |
BEI Level 1 |
|
| NR-52563 |
Modified pαH Vector Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Ectodomain |
BEI Level 1 |
|
| NR-52564 |
Modified pαH Vector Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein |
BEI Level 1 |
|
| NR-52565 |
Modified pαH Vector Containing the Human Angiotensin-Converting Enzyme 2 |
BEI Level 1 |
|
| NR-52897 |
Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Papain-Like Protease Gene |
BEI Level 1 |
|
| NR-52898 |
Vector pCSGID Containing the SARS-CoV-2, Wuhan-Hu-1 3C-Like Protease Gene |
BEI Level 1 |
|
| NR-52899 |
Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 1 Gene |
BEI Level 1 |
|
| NR-52900 |
Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 7 Gene |
BEI Level 1 |
|
| NR-52901 |
Vector pMCSG120 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 8 Gene |
BEI Level 1 |
|
| NR-52902 |
Vector pMCSG53 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 8 Gene |
BEI Level 1 |
|
| NR-52949 |
Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 1 Gene |
BEI Level 1 |
|
| NR-52950 |
Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 2 Gene |
BEI Level 1 |
|
| NR-52951 |
Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 4 Gene |
BEI Level 1 |
|
| NR-52953 |
Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 3C-Like Protease Gene, C145A Mutant |
BEI Level 1 |
|
| NR-52955 |
Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 7 Gene |
BEI Level 1 |
|
| NR-52956 |
Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 8 Gene |
BEI Level 1 |
|
| NR-52957 |
Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 9 Gene |
BEI Level 1 |
|
| NR-52958 |
Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 10 Gene |
BEI Level 1 |
|
| NR-52959 |
Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 11 Gene |
BEI Level 1 |
|
| NR-52960 |
Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 12 Gene |
BEI Level 1 |
|
| NR-52961 |
Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 13 Gene |
BEI Level 1 |
|
| NR-52962 |
Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA WA1/2020 Non-Structural Protein 14 Gene |
BEI Level 1 |
|
| NR-52963 |
Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Non-Structural Protein 15 Gene |
BEI Level 1 |
|
| NR-52965 |
Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 3a Gene |
BEI Level 1 |
|
| NR-52966 |
Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 3b Gene |
BEI Level 1 |
|
| NR-52967 |
Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Envelope Gene |
BEI Level 1 |
|
| NR-52968 |
Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Membrane Glycoprotein Gene |
BEI Level 1 |
|
| NR-52969 |
Vector pLVX-EF1a-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 6 Gene |
BEI Level 1 |
|
| NR-52970 |
Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 7a Gene |
BEI Level 1 |
|
| NR-52971 |
Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 7b Gene |
BEI Level 1 |
|
| NR-52972 |
Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 8 Gene |
BEI Level 1 |
|
| NR-52973 |
Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Nucleocapsid Gene |
BEI Level 1 |
|
| NR-52974 |
Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 9b Gene |
BEI Level 1 |
|
| NR-52975 |
Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 9c Gene |
BEI Level 1 |
|
| NR-52976 |
Vector pLVX-EF1α-IRES-Puro Containing the SARS-CoV-2, USA-WA1/2020 Open Reading Frame 10 Gene |
BEI Level 1 |
|
| NR-52977 |
Vector pLVX-EF1α-IRES-Puro Containing the Enhanced Green Fluorescent Protein |
BEI Level 1 |
|
| NR-53496 |
Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 1 Gene |
BEI Level 1 |
|
| NR-53497 |
Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 4 Gene |
BEI Level 1 |
|
| NR-53498 |
Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 6 Gene |
BEI Level 1 |
|
| NR-53499 |
Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 7 Gene |
BEI Level 1 |
|
| NR-53500 |
Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 8 Gene |
BEI Level 1 |
|
| NR-53501 |
Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 9 Gene |
BEI Level 1 |
|
| NR-53502 |
Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 10 Gene |
BEI Level 1 |
|
| NR-53503 |
Vector pFastbac1 Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 12 Gene |
BEI Level 1 |
|
| NR-53504 |
Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 13 Gene |
BEI Level 1 |
|
| NR-53505 |
Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 14 Gene |
BEI Level 1 |
|
| NR-53506 |
Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 15 Gene |
BEI Level 1 |
|
| NR-53507 |
Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Nucleocapsid Gene |
BEI Level 1 |
|
| NR-53508 |
Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Membrane Glycoprotein Gene |
BEI Level 1 |
|
| NR-53509 |
Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Open Reading Frame 3a Gene |
BEI Level 1 |
|
| NR-53510 |
Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Open Reading Frame 7a Gene |
BEI Level 1 |
|
| NR-53511 |
Vector pET-28a(+) Containing the SARS-CoV-2, Wuhan-Hu-1 Non-Structural Protein 16 Gene |
BEI Level 1 |
|
| NR-53587 |
Modified pαH Vector Containing the SARS-CoV-2, Wuhan-Hu-1 HexaPro Spike Glycoprotein Ectodomain |
BEI Level 1 |
|
| NR-53696 |
Vector pCMV/R Containing the SARS-CoV-2, Wuhan-Hu-1 Spike Glycoprotein Gene |
BEI Level 1 |
|
We anticipate a large number of requests from the research community for these reagents, and we cannot guarantee how quickly stock will become available. Please continue checking for updates.
If you wish to transfer SARS-CoV-2 materials, please use the guidance provided in the Emergency Use Simple Letter Agreement.
Coming Soon and Expected Availability
| Item Number |
Description |
Expected Availability |
AA Substitutions per GISAID* |
| Virus |
|
| NR-54020 |
SARS-CoV-2, hCoV-19/USA/CA_UCSD_5574/2020 (B.1.1.7) |
TBD |
Link to Mutations |
| NR-54981 |
SARS-CoV-2, hCoV-19/Japan/TY7-501/2021 (P.2) |
April 2021 |
Link to Mutations |
| NR-54985 |
SARS-CoV-2, hCoV-19/USA/MD-HP12112/2021 (B.1.1.207) |
April 2021 |
Link to Mutations |
| NR-54986 |
SARS-CoV-2, hCoV-19/USA/MD-HP12155/2020 (B.1.1.4) |
April 2021 |
Link to Mutations |
| NR-54987 |
SARS-CoV-2, hCoV-19/USA/MD-HP01101/2021 (B.1.1.7) |
April 2021 |
Link to Mutations |
| NR-55282 |
SARS-CoV-2, hCoV-19/USA/MD-HP01542/2021 (B.1.351) |
TBD |
Link to Mutations |
| NR-55331 |
SARS-CoV-2, hCoV-19/USA/CA (B.1.427) |
April 2021 |
|
| NR-55332 |
SARS-CoV-2, hCoV-19/USA/CA (B.1.429) |
April 2021 |
|
| NR-55359 |
SARS-CoV-2, hCoV-19/USA/NYDOH1/2021 (B.1.526) |
April 2021 |
|
| Nucleic Acid |
|
| NR-52389 |
Genomic RNA from SARS-CoV-2, Isolate New York-PV08001/2020 |
Early 2021 |
|
| NR-55346 |
Genomic RNA, SARS-CoV-2, Japan/TY7-503/2021 (Brazil P.1) |
May 2021 |
|
| NR-55349 |
Genomic RNA from SARS-CoV-2,USA/MD-HP01542/2021 (B.1.351) |
May 2021 |
|
| NR-55352 |
Genomic RNA from SARS-CoV-2,USA/CA/VRLC009/2021 (P.2. Brazil) |
May 2021 |
|
| Inactivated Organisms |
|
| NR-55347 |
Heat inactivated, SARS-CoV-2, Japan/TY7-503/2021 (Brazil P.1) |
May 2021 |
|
| NR-55353 |
Heat inactivated, SARS-CoV-2,USA/CA/VRLC009/2021 (P.2. Brazil) |
May 2021 |
|
| NR-55350 |
Heat inactivated, SARS-CoV-2,USA/MD-HP01542/2021 (B.1.351) |
May 2021 |
|
| NR-55348 |
Irradiated virus, SARS-CoV-2, Japan/TY7-503/2021 (Brazil P.1) |
May 2021 |
|
| NR-55354 |
Irradiated virus, SARS-CoV-2, USA/CA/VRLC009/2021 (P.2. Brazil) |
May 2021 |
|
| NR-55351 |
Irradiated virus, SARS-CoV-2,USA/MD-HP01542/2021 (B.1.351) |
May 2021 |
|
| Cell Line |
|
| NR-52511 |
Human Embryonic Kidney Cells (HEK-293T) Expressing Human Angiotensin-Converting Enzyme 2, HEK-293T-hACE2 Cell Line |
Summer 2021 |
|
| Monoclonal Antibody |
|
| NR-52392 |
Monoclonal Anti-SARS Coronavirus Recombinant Human IgG1, Clone CR3022 (produced in Nicotiana benthamiana) |
Early 2021 |
|
| NR-53788 |
Monoclonal Anti-SARS-CoV-2 Spike Glycoprotein S1 Domain (produced in vitro) |
May - June 2021 |
|
| NR-53791 |
Monoclonal Anti-SARS Coronavirus/SARS-CoV-2 Nucleocapsid Protein, rabbit MAb (produced in vitro) |
May - June 2021 |
|
| NR-53792 |
Monoclonal Anti-SARS Coronavirus/SARS-CoV-2 Nucleocapsid Protein, mouse MAb (produced in vitro) |
May - June 2021 |
|
| NR-55294 |
MAb, Anti-SARS-CoV-2 RBD protein-Clone 2TP1B3 |
May 2021 |
|
| NR-55295 |
MAb, Anti-SARS-CoV-2 RBD protein-Clone 2TP1B11 |
May 2021 |
|
| NR-55296 |
MAb, Anti-SARS-CoV-2 RBD protein-Clone 2TP1C3 |
May 2021 |
|
| NR-55297 |
MAb, Anti-SARS-CoV-2 RBD protein-Clone 2TP1D10 |
May 2021 |
|
| NR-55298 |
MAb, Anti-SARS-CoV-2 RBD protein-Clone 2TP1E6 |
May 2021 |
|
| NR-55299 |
MAb, Anti-SARS-CoV-2 RBD protein-Clone 2TP1F2 |
May 2021 |
|
| NR-55300 |
MAb, Anti-SARS-CoV-2 RBD protein-Clone 2TP2C2 |
May 2021 |
|
| NR-55301 |
MAb, Anti-SARS-CoV-2 RBD protein-Clone 2TP2C7 |
May 2021 |
|
| NR-55302 |
MAb, Anti-SARS-CoV-2 RBD protein-Clone 2TP2E7 |
May 2021 |
|
| NR-55303 |
MAb, Anti-SARS-CoV-2 RBD protein-Clone 2TP2F2 |
May 2021 |
|
| Protein |
|
| NR-53797 |
Nucleocapsid Protein from SARS-CoV-2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from Baculovirus |
May - June 2021 |
|
| NR-52348 |
Spike Glycoprotein from SARS-CoV-2, Wuhan-Hu-1, Recombinant from HEK293T Cells |
Early 2021 |
|
| NR-55307 |
Full length SARS-CoV-2 spike protein (P.1) |
April 2021 |
|
| NR-55310 |
Full length SARS-CoV-2 spike protein (B.1.351) |
April 2021 |
|
| NR-55311 |
Full length SARS-CoV-2 spike protein (B.1.1.7) |
April 2021 |
|
| NR-55277 |
Recombinant spike protein RBD, SARS-CoV-2 (B.1.1.7) |
May 2021 |
|
| NR-55278 |
Recombinant spike protein RBD, SARS-CoV-2 (B.1.351) |
May 2021 |
|
| Peptide Array |
|
| NR-52402 |
Peptide Array, SARS-CoV-2 Spike (S) Glycoprotein |
TBD |
|
| NR-52403 |
Peptide Array, SARS-CoV-2 Membrane (M) Protein |
TBD |
|
| NR-52404 |
Peptide Array, SARS-CoV-2 Nucleocapsid (N) Protein |
TBD |
|
| Plasmid |
|
| NR-52954 |
Plasmid pLVX-EF1α-IRES-Puro SARS-CoV-2, nsp6 (TST) |
Early 2021 |
|
| NR-53762 |
icSARS-CoV-2-WT, infectious cDNA USA-WA1/2020, plasmid Kit |
Early 2021 |
|
| NR-53763 |
icSARS-CoV-2-eGFP, infectious cDNA USA-WA1/2020, plasmid Kit |
Early 2021 |
|
| NR-53764 |
icSARS-CoV-2-nLuc, infectious cDNA USA-WA1/2020, plasmid Kit |
Early 2021 |
|
*Please see the Appendix section of the COA for variant analysis of each virus lot.
The BEI Resources catalog offers additional coronavirus materials ready and available for distribution to qualified laboratories.
For access to BEI Resources full catalog, click here.
Frequently Asked Questions
- Is there currently a shortage or delay in receiving SARS-CoV-2 virus isolates or RNA from BEI Resources?
- How long will it take to get SARS-CoV-2 materials?
- How long will it take to process my registration to receive SARS-CoV-2 materials?
- Who is qualified to receive SARS-CoV-2 materials?
- What level of registration do I need to receive SARS-CoV-2 materials?
- If I have questions regarding SARS-CoV-2 materials, who do I contact?
- How much do SARS-CoV-2 materials cost?
- What is the Emergency Use Simple Letter Agreement (EUSLA)?
- Which SARS-CoV-2 materials distributed by BEI fall under the EUSLA?
- Can I transfer SARS-CoV-2 materials?
- Can I commercialize SARS COV-2 materials?
- Are COVID-19 patient samples currently available from BEI Resources?
- How do I obtain test kits for COVID-19?
- Why is the SARS-CoV-2 genomic RNA only distributed to facilities which have BSL-2 laboratories?
- Am I required to obtain a CDC permit for the transfer of SARS-CoV-2 isolates?
- Where do I find product documentation (Product Sheet, Certificate of Analyses, etc.) for BEI Resources products?
- How do I find out about SARS-CoV-2 products coming soon?
Question: Is there currently a shortage or delay in receiving SARS-CoV-2 virus isolates or RNA from BEI Resources?
Answer: No, BEI Resources currently does not have a shortage or a delay in shipping virus and RNA to qualified laboratories. We understand how important it is to share virus strains and derivatives with researchers, especially during an outbreak.
Back to Questions
Question: How long will it take to get SARS-CoV-2 materials?
Answer: BEI Resources is prioritizing all SARS-CoV-2 shipments. Shipments are generally being made within 24-48 hours of completed requests. If permits are required, these timelines are dependent on obtaining those permits. Please contact us at contact@beiresources.org for any shipment questions.
Back to Questions
Question: How long will it take to process my registration to receive SARS-CoV-2 materials?
Answer: BEI Resources is prioritizing and fast tracking all SARS-CoV-2 registrations. We anticipate a 12-72 hour turn-around time for all SARS-CoV-2 related registrations. Please indicate SARS-CoV-2 in your scope of use. Please contact BEI Resources at contact@beiresources.org for questions.
Back to Questions
Question: Who is qualified to receive SARS-CoV-2 materials?
Answer: Registration with BEI Resources is required to request SARS-CoV-2 materials. BEI Resources reagents are shared with registered individuals and organizations doing research on Emerging Infections and other relevant areas of interest related to Microbiology. To register you must be affiliated with a public, private, academic, non-profit or for-profit institution. Registrants must demonstrate they work in an established institution with facilities and safety programs appropriate for the Level of registration requested.
Back to Questions
Question: What level of registration do I need to receive SARS-CoV-2 materials?
Answer: Each product on the BEI Resources website lists a BEI Resources level of registration. Interested researchers will need to ensure they are registered at the appropriate level to receive materials. Please click here for registration instructions. If you need to upgrade your registration to a higher level, please click here for instructions.
Back to Questions
Question: If I have questions regarding SARS-CoV-2 materials, who do I contact?
Answer: Please contact BEI Resources at contact@beiresources.org for any questions regarding SARS-CoV-2 materials.
Back to Questions
Question: How much do SARS-CoV-2 materials cost?
Answer: All BEI Resources reagents, including SARS-CoV-2 materials, are provided world-wide at no cost. While there is no cost for the reagents themselves, additional shipping and handling charges may apply and will display in the shopping cart if applicable.
Back to Questions
Question: What is the Emergency Use Simple Letter Agreement (EUSLA)?
Answer: The Emergency Use Simple Letter Agreement outlines the terms in which SARS-CoV-2 materials are being provided. In light of the emergence of the novel coronavirus, 2019-SARS-CoV-2, and urgent need to mitigate the pathogen’s spread, the EUSLA was instituted for the provision of these materials under the terms outlined in the agreement. The EUSLA is not negotiable.
Back to Questions
Question: Which SARS-CoV-2 materials distributed by BEI fall under the EUSLA?
Answer: The viruses, nucleic acids, and inactivated SARS-CoV-2 organisms, along with the gamma irradiated NHP convalescent serum from SARS-CoV-2, are distributed under the terms of the EUSLA. Please note that the signature of the biosafety officer to certify that your facility can safely handle the material is required for receipt of the virus. The following is a list of items distributed by BEI under the EUSLA:
| Item Number |
Description |
| NR-52281 |
SARS-CoV-2, Isolate USA-WA1/2020 |
| NR-52282 |
SARS-CoV-2, Isolate Hong Kong/VM20001061/2020 |
| NR-52284 |
SARS-CoV-2, Isolate Italy-INMI1 |
| NR-52359 |
SARS-CoV-2, Isolate England/02/2020 |
| NR-52368 |
SARS-CoV-2, Isolate New York 1-PV08001/2020 |
| NR-52369 |
SARS-CoV-2, Isolate Singapore/2/2020 |
| NR-52370 |
SARS-CoV-2, Isolate Germany/BavPat1/2020 |
| NR-52381 |
SARS-CoV-2, Isolate USA-IL1/2020 |
| NR-52382 |
SARS-CoV-2, Isolate USA-CA1/2020 |
| NR-52383 |
SARS-CoV-2, Isolate USA-AZ1/2020 |
| NR-52384 |
SARS-CoV-2, Isolate USA-WI1/2020 |
| NR-52385 |
SARS-CoV-2, Isolate USA-CA3/2020 |
| NR-52386 |
SARS-CoV-2, Isolate USA-CA4/2020 |
| NR-52387 |
SARS-CoV-2, Isolate USA-CA2/2020 |
| NR-52439 |
SARS-CoV-2, Isolate Chile/Santiago_op4d1/2020 |
| NR-53514 |
SARS-CoV-2, Isolate New York-PV08410/2020 |
| NR-53515 |
SARS-CoV-2, Isolate New York-PV08449/2020 |
| NR-53516 |
SARS-CoV-2, Isolate New York-PV09158/2020 |
| NR-53517 |
SARS-CoV-2, Isolate New York-PV09197/2020 |
| NR-53565 |
SARS-CoV-2, Isolate Canada/ON/VIDO-01/2020 |
| NR-53944 |
SARS-CoV-2, Isolate hCoV-19/Scotland/CVR837/2020 |
| NR-53945 |
SARS-CoV-2, Isolate hCoV-19/Scotland/CVR2224/2020 |
| NR-53953 |
SARS-CoV-2, Isolate hu/DK/CL-5/1 |
| NR-54000 |
SARS-CoV-2 hCoV-19/England/204820464/2020 |
| NR-54008 |
SARS-CoV-2 hCoV-19/South Africa/KRISP-EC-K005321/2020 |
| NR-54009 |
SARS-CoV-2 Isolate hCoV-19/South Africa/KRISP-K005325/2020 |
| NR-54011 |
SARS-CoV-2 Isolate hCoV-19/USA/CA_CDC_5574/2020 |
| NR-54982 |
SARS-CoV-2 Isolate hCoV-19/Japan/TY7-503/2021 |
| NR-52285 |
Genomic RNA from SARS-CoV-2, Isolate USA-WA1/2020 |
| NR-52388 |
Genomic RNA from SARS-CoV-2, Isolate Hong Kong/VM20001061/2020 |
| NR-52498 |
Genomic RNA from SARS-CoV-2, Isolate Italy-INMI1 |
| NR-52499 |
Genomic RNA from SARS-CoV-2, Isolate England/02/2020 |
| NR-52501 |
Genomic RNA from SARS-CoV-2, Isolate Singapore/2/2020 |
| NR-52502 |
Genomic RNA from SARS-CoV-2, Isolate Germany/BavPat1/2020 |
| NR-52503 |
Genomic RNA from SARS-CoV-2, Isolate USA-IL1/2020 |
| NR-52504 |
Genomic RNA from SARS-CoV-2, Isolate USA-CA1/2020 |
| NR-52505 |
Genomic RNA from SARS-CoV-2, Isolate USA-AZ1/2020 |
| NR-52506 |
Genomic RNA from SARS-CoV-2, Isolate USA-WI1/2020 |
| NR-52507 |
Genomic RNA from SARS-CoV-2, Isolate USA-CA3/2020 |
| NR-52508 |
Genomic RNA from SARS-CoV-2, Isolate USA-CA4/2020 |
| NR-52509 |
Genomic RNA from SARS-CoV-2, Isolate USA-CA2/2020 |
| NR-52510 |
Genomic RNA from SARS-CoV-2, Isolate Chile/Santiago_op4d1/2020 |
| NR-53518 |
Genomic RNA from SARS-CoV-2, Isolate New York-PV08410/2020 |
| NR-55244 |
Genomic RNA from SARS-CoV-2 Isolate hCoV-19/USA/CA_CDC_5574/2020 |
| NR-52347 |
Quantitative PCR (qPCR) Control RNA from Heat-Inactivated SARS-CoV-2, Isolate USA-WA1/2020 |
| NR-52286 |
SARS-CoV-2, Isolate USA-WA1/2020, Heat Inactivated |
| NR-52287 |
SARS-CoV-2, Isolate USA-WA1/2020, Gamma-Irradiated |
| NR-52350 |
Quantitative PCR (qPCR) Extraction Control from Heat-Inactivated SARS-CoV-2, Isolate USA-WA1/2020 |
| NR-52401 |
Pooled Non-Human Primate Convalescent Serum to SARS-CoV-2, Gamma-Irradiated |
| NR-53593 - NR-53692 |
SARS-CoV-2, Human Plasma and PBMC Samples |
| NR-53736 |
SARS-CoV-2, Human Peripheral Blood Mononuclear Cells (PBMC), Subject ID: LPEQAP142 |
| NR-53737 |
SARS-CoV-2, Human Plasma, Subject ID: LPEQAP142 |
| NR-53738 |
SARS-CoV-2, Human Serum, Subject ID: 0873-294 |
Back to Questions
Question: Can I transfer SARS-CoV-2 materials?
Answer: “Material” as used in this answer, means the original material or any unmodified progeny received from BEI Resources. SARS-CoV-2 materials received under the EUSLA may be further distributed to other entities for legitimate purposes required to rapidly prevent, detect, prepare for, and respond to, the spread or transmission of SARS-CoV-2 and under terms no more restrictive than the Emergency Use Simple Letter Agreement (EUSLA). To ensure compliance with this, copies of the EUSLA or MTAs recording all further transfers must be sent back to contact@beiresources.org. This requirement must also be incorporated for further transfers. The recipient and provider agree to transfer, use, manage, and control the SARS-CoV-2 materials in compliance with all applicable laws and regulations. When these commodities, technology or software are exported from the United States, the recipient agrees to comply with the Export Administration Regulations. Diversion contrary to U.S. law is prohibited.
Any products made by you, that are not considered the original material or unmodified progeny, are excluded from this requirement, and you are free to share and commercialize those products as your own products.
Back to Questions
Question: Can I commercialize SARS COV-2 materials?
Answer: “Material” as used in this answer, means the original material or any unmodified progeny received from BEI Resources. SARS-CoV-2 materials received under the EUSLA are made available for any legitimate purpose, including commercial purposes, as long as they are to rapidly prevent, detect, prepare for, and respond to, the spread or transmission of the 2019 SARS-CoV-2. Any transfer of the original material or any unmodified progeny must be done under the terms of the EUSLA (see question above regarding transfer of SARS-CoV-2 materials). Any products made by you, that are not considered the original material or unmodified progeny, are excluded from this requirement, and you are free to share and commercialize those products as your own products.
Back to Questions
Question: Are COVID-19 patient samples currently available from BEI Resources?
Answer: We understand how important it is to share patient samples, including sera, nasal swabs and PBMCs, with researchers, especially during an outbreak. We will have a very limited number of samples available. Requestors must limit their orders to 5 samples of serum/plasma. We anticipate a large number of requests from the research community for patient samples related to the pandemic, and will continually work towards making more samples available. Please order according to the limits above and contact our email box at contact@beiresources.org with any questions. If we are not able to fill your needs, please contact us so we can forward your request to NIAID to prioritize those samples once available.
Back to Questions
Question: How do I obtain test kits for COVID-19?
Answer: Test kits are not distributed through BEI Resources. The CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel was developed for qualified domestic public health laboratories to detect SARS-CoV-2. The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) on February 4, 2020, to enable emergency use of the test kit in the United States. CDC has produced EUA and Research Use Only (RUO) test kits that are now available to order by domestic and international public health partners through IRR (www.internationalreagentresource.org). Please contact the International Reagent Resources program for more information – contact@internationalreagentresource.org.
Back to Questions
Question: Why is the SARS-CoV-2 genomic RNA only distributed to facilities which have BSL-2 laboratories?
Answer: CDC guidelines state that molecular analysis of extracted nucleic acid preparations should be performed in BSL-2 facility using standard BSL-2 work practices. The CDC guidelines can be found in the following link: https://www.cdc.gov/coronavirus/2019-nCoV/lab/lab-biosafety-guidelines.html
Back to Questions
Question: Am I required to obtain a CDC permit for the transfer of SARS-CoV-2 isolates?
Answer: The BEI Resources website provides a link on each product detail page for applicable permits. Please check the individual product detail pages for this information. SARS-CoV-2 isolates which originate from the United States do not require a CDC permit for domestic transfer. SARS-CoV-2 isolates which are deposited into BEI Resources outside of the USA, will be brought into the repository under a CDC permit, and will require a CDC permit for transfer.
Back to Questions
Question: Where do I find product documentation (Product Sheet, Certificate of Analyses, etc.) for BEI Resources products?
Answer: All Product Sheets and Certificates of Analysis can be found on the BEI Resources website. Perform a search for the product, and you will find the documentation. Any product listed as requiring a BSL-3 facility, will require login first to view the documentation. Only BEI Level 3 registrants will have access to view and download products requiring BSL-3 facilities.
Back to Questions
Question: How do I find out about SARS-CoV-2 products coming soon?
Answer: BEI Resources will list the status of SARS-CoV-2 products coming soon in the table above titled Coming Soon and Expected Availability.
Back to Questions
Forms
Emergency Use Simple Letter Agreement (EUSLA)
Back to the top
|